{"entity":{"id":"kt-200","kind":"drug","name":"KT-200","aka":[],"tldr":"KT-200 is an experimental molecular glue degrader from Kymera Therapeutics, in preclinical development for CCNE1-amplified or over-expressed cancers and breast cancer.","summary":"KT-200 is a molecular glue degrader (oral) from Kymera Therapeutics, with Gilead Sciences as licensee. An oral molecular glue degrader designed to remove CDK2 while sparing other CDK family proteins; CDK2 partners cyclin E and drives CCNE1-amplified and over-expressed cancers. Its furthest stage is preclinical development, for CCNE1-amplified or over-expressed cancers and breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Gilead is running IND-enabling studies toward an IND filing in 2027 (Kymera 8-K, 29 Oct 2026). It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Kymera Therapeutics: biospace.com","url":"https://www.biospace.com/press-releases/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200-oral-cdk2-molecular-glue-degrader-development-candidate"},{"label":"Kymera Therapeutics: biospace.com","url":"https://www.biospace.com/press-releases/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200-oral-cdk2-molecular-glue-degrader-development-candidate"},{"label":"Kymera Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cdk2"],"drugs":[],"companies":["kymera","gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"KT-200","modality":"Molecular glue degrader (oral)","mechanism":"An oral molecular glue degrader designed to remove CDK2 while sparing other CDK family proteins; CDK2 partners cyclin E and drives CCNE1-amplified and over-expressed cancers.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/kt-200/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"},{"id":"kymera","kind":"company","name":"Kymera Therapeutics","route":"/companies/kymera/"}]}}